Neumora Therapeutics Inc (NMRA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.31-2.96%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NMRA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Maintain sufficient cash and cash equivalents to fund operating plan through the third quarter of 2027.
Stated as a priority in 5 of last 5 quarters. Cash and cash equivalents declined from $182.5 million at 2025-Q4 to $116.8 million at 2026-Q2. Despite the decline, management consistently expects cash to fund operations into Q3 2027, indicating delivery on the stated runway objective.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The Company expects that its cash and cash equivalents as of June 30, 2026, will enable it to fund its operating plan into the third quarter of 2027.”
“The Company expects that its cash and cash equivalents as of March 31, 2026, will enable it to fund its operating plan into the third quarter of 2027.”
“The Company expects that its cash, cash equivalents and marketable securities as of December 31, 2025, will enable it to fund its operating plan into the third quarter of 2027.”
“The Company expects that its cash, cash equivalents and marketable securities as of September 30, 2025, will enable it to fund its operating plan into 2027.”
“The Company expects that its cash, cash equivalents and marketable securities as of June 30, 2025, will enable it to fund its operating plan into 2027.”
Progress clinical development of NMRA-511 with data readouts and initiation of Phase 2 study in Alzheimer’s disease agitation by early 2027.
Stated as a priority in 2 of last 2 quarters. Management plans data readout from the MAD expansion cohort in late 2026 and Phase 2 study initiation by early 2027. Progress is consistent with stated timelines, showing delivery on clinical advancement milestones.
“Neumora plans to report data from a MAD expansion cohort evaluating higher doses of NMRA-511 in the fourth quarter of 2026 and to initiate a Phase 2 study by the end of 2026.”
“We remain on track to report data from the MAD expansion cohort in the second half of 2026, with a Phase 2 study anticipated to begin in the first quarter of 2027.”
Submit IND and initiate Phase 1 study for NMRA-215 in obesity and cardiometabolic disease by end of 2026.
Stated as a priority in 2 of last 2 quarters. Management plans IND submission and Phase 1 initiation for NMRA-215 by end of 2026, consistent with recent toxicology results and program updates. The trajectory matches stated clinical advancement goals.
“Neumora is developing NMRA-215 for obesity and cardiometabolic disease with a plan to submit IND in Q4 2026 and initiate Phase 1 study by end of 2026.”
“The Company expects to provide a program update in the second half of 2026 and for the program to enter the clinic in the first quarter of 2027.”
Implement workforce reduction to realize approximately $10 million in annualized cost savings.
Newly stated in 2026-Q2. Management expects $10 million annualized cost savings from workforce reduction. R&D expenses declined by $9.3 million and G&A by $1.4 million from 2026-Q1 to 2026-Q2, indicating initial progress toward cost savings.
“The Company expects the reduction in force to result in an annualized cost savings of approximately $10 million.”
Discontinue navacaprant development following failure to meet primary endpoints in Phase 3 KOASTAL-2 and -3 studies.
Over the trailing year it converted 0.71x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
9 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.